Glenmark Pharmaceuticals receives USFDA final approval for Abiraterone Acetate Tablets

20 May 2022 , 09:10 AM

Glenmark Pharmaceuticals Inc., USA (Glenmark) has received final approval by the United States Food & Drug Administration (U.S. FDA) for Abiraterone Acetate Tablets USP, 500 mg, the generic version of Zytiga?1 Tablets, 500 mg, of Janssen Biotech Inc. According to IQVIATM sales data for the 12 month period ending March 2022, the Zytiga? Tablets, 500 mg market achieved annual sales of approximately $260.2 million. Glenmarks current portfolio consists of 173 products authorized for distribution in the U.S. marketplace and 49 ANDAs pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio. Powered by Capital Market – Live News